DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Global clinical trials market will reach $79,977.1 million by 2031, growing by 7.0% annually over 2022-2031, driven by the increasing number of clinical trials and increase in demand for novel ...